

**Table 8.6g**  
**Immunosuppression Use for Maintenance Between Discharge**  
**and One Year Following Transplantation, 1997 to 2006**  
**Recipients with Kidney-Pancreas Transplants**

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
<b>Transplants</b>	853	972	941	915	891	905	871	881	903	924
<b>Tx with Follow-up Immunosuppression Info</b>	781	869	859	840	818	820	785	783	824	809
<b>Corticosteroids</b>										
Any in Category	99.9%	99.7%	99.5%	95.6%	93.4%	89.4%	81.9%	75.7%	73.5%	72.4%
Steroids	99.9%	99.7%	99.5%	95.6%	93.4%	89.4%	81.9%	75.7%	73.5%	72.4%
<b>Cyclosporine</b>										
Any in Category	48.7%	36.2%	31.1%	23.0%	17.0%	13.4%	11.8%	8.7%	7.3%	7.0%
Cyclosporin	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%
Sandimmune	8.6%	4.1%	5.0%	3.1%	1.8%	1.3%	0.6%	0.5%	0.1%	0.1%
Neoral	40.1%	32.1%	25.8%	18.7%	12.3%	8.8%	9.2%	6.8%	5.5%	5.6%
Gengraf	0.0%	0.0%	0.2%	1.2%	2.7%	3.2%	2.0%	1.4%	1.7%	1.4%
Eon	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
<b>Tacrolimus</b>										
Any in Category	62.4%	75.3%	80.7%	84.3%	89.4%	89.9%	87.6%	87.6%	93.3%	92.1%
Tacrolimus	62.4%	75.3%	80.7%	84.3%	89.4%	89.9%	87.6%	87.6%	93.3%	92.1%
<b>Antimetabolites</b>										
Any in Category	96.0%	96.8%	95.7%	87.6%	80.4%	82.2%	82.5%	86.3%	86.4%	87.8%
Mycophenolate Mofetil	82.1%	85.0%	87.4%	81.3%	77.5%	79.8%	80.3%	79.8%	75.1%	69.7%
Mycophenolate Sodium	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.7%	10.2%	15.9%
Azathioprine	14.0%	11.7%	8.3%	6.3%	2.9%	2.4%	2.2%	1.7%	0.8%	1.2%
Leflunomide	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.2%	0.9%
Cytosan	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
<b>mTOR Inhibitors</b>										
Any in Category	0.0%	2.0%	5.2%	21.0%	31.2%	27.7%	27.5%	24.3%	22.2%	19.4%
Sirolimus	0.0%	0.9%	4.8%	20.5%	31.1%	27.7%	27.5%	24.3%	22.2%	19.4%
Everolimus	0.0%	1.0%	0.5%	0.5%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation. Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.